Paula Ragan, X4 Pharmaceuticals CEO
April 29, 2024 07:34 AM EDTUpdated 09:27 AM
Pharma
FDA+

FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

Lei Lei Wu

News Reporter

X4 Phar­ma­ceu­ti­cals an­nounced Mon­day morn­ing that the FDA ap­proved its dai­ly pill for WHIM syn­drome — an ul­tra-rare im­mune dis­ease named af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

A service from the Financial Times